12/31/2023 0 Comments Renflexis copay assistance![]() market last year, J&J hasn’t seen as much impact from the competition as was expected, Gorsky said. Regardless, the presence of a second biosimilar shouldn’t impact Remicade earnings this year as J&J already has annual contracts in place for its blockbuster immunology drug, Gorsky noted.Īlthough Pfizer’s Inflectra hit the U.S. During the company’s second-quarter earnings call in July, CEO Alex Gorsky said the Renflexis launch wasn’t expected until later this year. The immediate launch may have caught J&J, of New Brunswick, N.J., a bit off guard. an opportunity to see what the biosimilar experience looks like vs. Merck also plans to roll out a Renflexis website to give patients one-stop access to information about the drug, related services and PAPs.īringing together the steeper discount and the support associated with biologics, the launch of Renflexis will give the U.S. They’ll have “essentially the same patient support and services that you’d expect for any Merck product,” Consalvo said. ![]() ![]() So along with the discount, Merck will offer Renflexis patients support services and patient assistance programs (PAPs). Since infliximab is a specialty drug that’s infused in a provider setting, Renflexis will compete as if it were in a brand market rather than a generic market, which generally doesn’t offer all the support and reimbursement services that specialty biologics are expected to provide, Robert Consalvo, a Merck spokesman, told BioWorld. Prior to that ruling, biosimilar launches were delayed at least six months following FDA approval. Amgen Inc., in which the court said biosimilar sponsors don’t have to wait for approval before giving the innovator the required 180-day notice of commercial marketing. Approved by the FDA in April, Renflexis is the first biosimilar to benefit from June’s U.S. The launch of the follow-on marks yet another first. With the launch of Renflexis, Remicade becomes the first biologic to have two biosimilars on the U.S. – at a 15 percent discount in November, reflecting what has been the market norm for a first biosimilar. launched the first Remicade biosimilar – Inflectra, partnered with South Korea’s Celltrion Inc. That’s the steepest discount offered for a biosimilar in the U.S. Ltd., set the list price for the tumor necrosis factor (TNF) blocker at $753.39, a 35 percent discount to the current list price of Remicade. in partnership with South Korea’s Samsung Bioepsis Co. Merck, which is commercializing the biosimilar in the U.S. Inc., of Kenilworth, N.J., announced last week the immediate launch of Renflexis, the second FDA-approved biosimilar referencing Johnson & Johnson’s (J&J) Remicade (infliximab). is on the brink of seeing the potential impact a competitive biosimilar market could have on drug prices and accessibility. Darts-ip Design and Model Case Law Data.Transform the way you create, manage and protect intellectual property. Commercial Effectiveness & Launch Strategy.OFF-X Preclinical and Clinical Safety Intelligence.Portfolio Strategy & Business Development Advance innovation and accelerate patient outcomes.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |